S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
NYSE:DNA

Ginkgo Bioworks Stock Forecast, Price & News

$4.52
-0.13 (-2.80%)
(As of 01/28/2022 10:40 AM ET)
Add
Compare
Today's Range
$4.42
▼
$4.80
50-Day Range
$4.65
▼
$13.49
52-Week Range
$4.34
▼
$15.86
Volume
109,857 shs
Average Volume
12.80 million shs
Market Capitalization
$6.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive DNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.


Ginkgo Bioworks logo

About Ginkgo Bioworks

Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.

Headlines

Ginkgo Bioworks initiated Buy at BofA on recent selloff
January 28, 2022 |  seekingalpha.com
Ginkgo Bioworks (NYSE:DNA) Coverage Initiated at Bank of America
January 28, 2022 |  americanbankingnews.com
Ginkgo Bioworks (NYSE:DNA) Shares Gap Down to $5.13
January 25, 2022 |  americanbankingnews.com
Ginkgo Bioworks (NYSE:DNA) Sets New 52-Week Low at $4.77
January 24, 2022 |  americanbankingnews.com
Ginkgo Bioworks (NYSE:DNA) Trading 4.5% Higher
January 21, 2022 |  americanbankingnews.com
Ginkgo Bioworks acquires Boston-based testing provider Project Beacon COVID-19
January 19, 2022 |  seekingalpha.com
Ginkgo Bioworks (NYSE:DNA) Trading Down 4.5%
January 19, 2022 |  americanbankingnews.com
Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed
January 19, 2022 |  benzinga.com
Ginkgo Bioworks Announces Acquisition of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC
January 19, 2022 |  finance.yahoo.com
Ginkgo Bioworks Holdings Inc (NYSE:DNA) Expected to Announce Earnings of -$0.04 Per Share
January 18, 2022 |  americanbankingnews.com
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
January 18, 2022 |  benzinga.com
Ginkgo Bioworks (NYSE:DNA) Reaches New 52-Week Low at $5.24
January 18, 2022 |  americanbankingnews.com
Guild Investment Management, Inc. Buys The Mosaic Co, ProShares S&P 500 Dividend ...
January 18, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:DNA
Previous Symbol
CUSIP
N/A
CIK
1830214
Web
www.eagleequityptnrs.com
Phone
877-442-5362
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
20.05
Quick Ratio
20.01

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
1,486,734,000
Free Float
N/A
Market Cap
$6.72 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/28/2022
Next Earnings (Estimated)
2/21/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.16 out of 5 stars

Medical Sector

461st out of 1,417 stocks

Biological Products, Except Diagnostic Industry

70th out of 207 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Ginkgo Bioworks (NYSE:DNA) Frequently Asked Questions

Is Ginkgo Bioworks a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ginkgo Bioworks stock.
View analyst ratings for Ginkgo Bioworks or view top-rated stocks.

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 71,830,000 shares, an increase of 30.0% from the December 31st total of 55,270,000 shares. Based on an average trading volume of 8,730,000 shares, the days-to-cover ratio is currently 8.2 days. Currently, 8.6% of the company's shares are short sold.
View Ginkgo Bioworks' Short Interest.

When is Ginkgo Bioworks' next earnings date?

Ginkgo Bioworks is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Ginkgo Bioworks.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings Inc (NYSE:DNA) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.03. The company had revenue of $77.61 million for the quarter, compared to analysts' expectations of $46 million.
View Ginkgo Bioworks' earnings history.

What price target have analysts set for DNA?

6 equities research analysts have issued 1-year price objectives for Ginkgo Bioworks' shares. Their forecasts range from $8.00 to $18.00. On average, they anticipate Ginkgo Bioworks' stock price to reach $13.00 in the next year. This suggests a possible upside of 187.6% from the stock's current price.
View analysts' price targets for Ginkgo Bioworks or view top-rated stocks among Wall Street analysts.

What is Ginkgo Bioworks' stock symbol?

Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (7.36%), Cutler Group LP (0.00%), Carnegie Capital Asset Management LLC (0.01%), Foundations Investment Advisors LLC (0.01%), Guild Investment Management Inc. (0.01%) and Exchange Traded Concepts LLC (0.00%).

Which major investors are selling Ginkgo Bioworks stock?

DNA stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC.

Which major investors are buying Ginkgo Bioworks stock?

DNA stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Cutler Group LP, Exchange Traded Concepts LLC, Guild Investment Management Inc., Hellman Jordan Management Co. Inc. MA, Carnegie Capital Asset Management LLC, Foundations Investment Advisors LLC, and Tuttle Capital Management LLC.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ginkgo Bioworks' stock price today?

One share of DNA stock can currently be purchased for approximately $4.52.

How much money does Ginkgo Bioworks make?

Ginkgo Bioworks has a market capitalization of $6.72 billion.

How many employees does Ginkgo Bioworks have?

Ginkgo Bioworks employs 2,021 workers across the globe.

What is Ginkgo Bioworks' official website?

The official website for Ginkgo Bioworks is www.eagleequityptnrs.com.

Where are Ginkgo Bioworks' headquarters?

Ginkgo Bioworks is headquartered at 955 Fifth Avenue, New York NY, 10075.

How can I contact Ginkgo Bioworks?

Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The company can be reached via phone at 877-442-5362.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.